Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02019329 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02019329 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 32 participants.
The verdict
NCT02019329, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This randomized, double-blinded, placebo-controlled study will investigate the safety, tolerability, and pharmacokinetics of multiple doses of RO5545965 administered orally to psychiatrically stable patients with schizophrenia receiving risperidone.
Interventions
- OTHER Placebo
- DRUG risperidone
- DRUG RO5545965
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02019329
The ClinicalTrials.gov registry entry for NCT02019329 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02019329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02019329 about?
NCT02019329 is a clinical study titled "A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone". This randomized, double-blinded, placebo-controlled study will investigate the safety, tolerability, and pharmacokinetics of multiple doses of RO5545965 administered orally to psychiatrically stable patients with schizophrenia receiving risperidone.
What is the current status of trial NCT02019329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-01. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02019329?
The interventions under investigation include: Placebo (OTHER), risperidone (DRUG), RO5545965 (DRUG).
Who is sponsoring clinical trial NCT02019329?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.